| HMDB0000012 | Deoxyuridine | 951-78-0 |  | C9H12N2O5 | 228.202
228.074621504 | Not Available |
| HMDB0000014 | Deoxycytidine | 951-77-9 |  | C9H13N3O4 | 227.2172
227.090605919 | Not Available |
| HMDB0000051 | Ammonia | 7664-41-7 |  | H3N | 17.0305
17.026549101 | Not Available |
| HMDB0000089 | Cytidine | 65-46-3 |  | C9H13N3O5 | 243.2166
243.085520541 | Not Available |
| HMDB0000296 | Uridine | 58-96-8 |  | C9H12N2O6 | 244.2014
244.069536126 | Not Available |
| HMDB0002111 | Water | 7732-18-5 |  | H2O | 18.0153
18.010564686 | Not Available |
| HMDB0014584 | Gemcitabine | 95058-81-4 |  | C9H11F2N3O4 | 263.1981
263.071762265 | - Wong A, Soo RA, Yong WP, Innocenti F: Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev. 2009;41(2):77-88. doi: 10.1080/03602530902741828. [PubMed:19514966 ]
- Giovannetti E, Laan AC, Vasile E, Tibaldi C, Nannizzi S, Ricciardi S, Falcone A, Danesi R, Peters GJ: Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):720-5. doi: 10.1080/15257770802145447. [PubMed:18600531 ]
- Gusella M, Pasini F, Bolzonella C, Meneghetti S, Barile C, Bononi A, Toso S, Menon D, Crepaldi G, Modena Y, Stievano L, Padrini R: Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol. 2011 Mar;71(3):437-44. doi: 10.1111/j.1365-2125.2010.03838.x. [PubMed:21284703 ]
|
| HMDB0015063 | Azacitidine | 320-67-2 |  | C8H12N4O5 | 244.2047
244.080769514 | - Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S: A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008 Sep;22(9):1680-4. doi: 10.1038/leu.2008.145. Epub 2008 Jun 12. [PubMed:18548103 ]
|
| HMDB0015122 | Cytarabine | 147-94-4 |  | C9H13N3O5 | 243.2166
243.085520541 | - Lamba JK: Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74. doi: 10.2217/pgs.09.118. [PubMed:19842938 ]
- Ohta T, Hori H, Ogawa M, Miyahara M, Kawasaki H, Taniguchi N, Komada Y: Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells. Oncol Rep. 2004 Nov;12(5):1115-20. [PubMed:15492802 ]
|
| HMDB0015233 | Capecitabine | 154361-50-9 |  | C15H22FN3O6 | 359.3501
359.149263656 | - de Bono JS, Twelves CJ: The oral fluorinated pyrimidines. Invest New Drugs. 2001;19(1):41-59. [PubMed:11291832 ]
- Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y: A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res. 2001 Aug;18(8):1190-202. [PubMed:11587492 ]
- Ishitsuka H, Shimma N, Horii I: [Discovery and development of novel anticancer drug capecitabine]. Yakugaku Zasshi. 1999 Dec;119(12):881-97. [PubMed:10630095 ]
- Ishitsuka H: Capecitabine: preclinical pharmacology studies. Invest New Drugs. 2000 Nov;18(4):343-54. [PubMed:11081570 ]
- Endo M, Miwa M, Eda H, Ura M, Tanimura H, Ishikawa T, Miyazaki-Nose T, Hattori K, Shimma N, Yamada-Okabe H, Ishitsuka H: Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. Int J Cancer. 2003 Sep 20;106(5):799-805. [PubMed:12866042 ]
|
| HMDB0060405 | 5'-Deoxy-5-fluorocytidine | |  | C9H12FN3O4 | 245.2077
245.081184092 | Not Available |
| HMDB0060406 | 5'-Deoxy-5-fluorouridine | |  | C9H11FN2O5 | 246.1924
246.065199677 | Not Available |
